Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury

Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1689-96. doi: 10.1161/ATVBAHA.114.303939. Epub 2014 Jun 12.

Abstract

Objective: Platelet-neutrophil interactions play a key role in cardiovascular disease and inflammatory processes. Src family kinases mediate P-selectin glycoprotein ligand-1-Mac-1 cross talk necessary for firm platelet-neutrophil adhesion. Because Src family kinase activity can be regulated by cAMP-dependent pathways, in this work, we evaluated the role of phosphodiesterases in the signaling events that are required to sustain platelet-neutrophil interactions and neutrophil recruitment at the site of vascular injury.

Approach and results: In neutrophils exposed to P-selectin, selective phosphodiesterase 4 (PDE4) inhibition prevented Src family kinase-mediated phosphorylation of the proline-rich tyrosine kinase 2 on Tyr579/Tyr580. The effects of PDE4 inhibition required protein kinase A, likely through protein kinase A-mediated activation of COOH-terminal Src kinase, a major negative regulator of Src family kinases. PDE4, but not other phosphodiesterase inhibitors, reduced platelet-neutrophil conjugates as well as neutrophil firm adhesion on spread platelets under flow conditions. The effect of PDE4 inhibition on neutrophil adhesion was primarily mediated by downregulation of P-selectin-induced activation of Mac-1. In a murine model of endovascular injury, selective inhibition of PDE4 significantly reduced neutrophil recruitment at the site of vascular damage.

Conclusions: This study identifies PDE4 as a central node in the signaling network that mediates platelet-neutrophil adhesion and suggests that pharmacological inhibition of PDE4 may represent a novel therapeutic avenue for the treatment of cardiovascular disease.

Keywords: neutrophils; phosphodiesterase 4 inhibitors; platelets.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / pharmacology
  • Animals
  • Blood Platelets / drug effects*
  • Blood Platelets / enzymology
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Disease Models, Animal
  • Femoral Artery / drug effects*
  • Femoral Artery / enzymology
  • Femoral Artery / injuries
  • Focal Adhesion Kinase 2 / metabolism
  • Humans
  • Macrophage-1 Antigen / genetics
  • Macrophage-1 Antigen / metabolism
  • Mice
  • Mice, Knockout
  • Neutrophil Infiltration / drug effects*
  • Neutrophils / drug effects*
  • Neutrophils / enzymology
  • P-Selectin / genetics
  • P-Selectin / metabolism*
  • Phosphodiesterase 4 Inhibitors / pharmacology*
  • Phosphorylation
  • Platelet Adhesiveness / drug effects*
  • Rolipram / pharmacology
  • Signal Transduction / drug effects
  • Time Factors
  • Vascular System Injuries / blood
  • Vascular System Injuries / drug therapy*
  • Vascular System Injuries / enzymology
  • src-Family Kinases / metabolism

Substances

  • Macrophage-1 Antigen
  • P-Selectin
  • Phosphodiesterase 4 Inhibitors
  • SELP protein, human
  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
  • Focal Adhesion Kinase 2
  • PTK2B protein, human
  • src-Family Kinases
  • Cyclic AMP-Dependent Protein Kinases
  • Rolipram